International Journal of Science and Research Archive
eISSN: 2582-8185
Cross Ref DOI: 10.30574/ijsra
Journal homepage: https://ijsra.net/

(REVIEW ARTICLE)

Check for updates

Artificial intelligence in pharmaceutical technology and drug delivery design in Uganda

Nakachwa Alice [1] and Onyango Laban Oliver Owin [2,*]

[1] *Graduate School Ndejje University, Uganda.*
[2] *Department of Computing and Information Technology School of Science and Computing, Ndejje University, Uganda.*

International Journal of Science and Research Archive, 2024, 12(02), 153–156

Publication history: Received on 07 May 2024; revised on 29 June 2024; accepted on 02 July 2024

Article DOI: https://doi.org/10.30574/ijsra.2024.12.2.1104

Abstract

Artificial intelligence (AI) has emerged as a powerful tool that harnesses anthropomorphic knowledge and provides expedited solutions to complex challenges. Remarkable advancements in AI technology and machine learning present a transformative opportunity in Uganda's drug discovery, formulation, and testing of pharmaceutical dosage forms. Researchers can identify disease-associated targets and predict their interactions with potential drug candidates by utilizing AI algorithms that analyze extensive biological data, including genomics and proteomics. This enables a more efficient and targeted approach to drug discovery, thereby increasing the likelihood of successful drug approvals in Uganda. Furthermore, AI can contribute to reducing development costs by optimizing research and development processes in Uganda's pharmaceutical industry. Machine learning algorithms assist in experimental design and can predict the pharmacokinetics and toxicity of drug candidates in Uganda. This capability enables the prioritization and optimization of lead compounds, reducing the need for extensive and costly animal testing in Uganda. Personalized medicine approaches can be facilitated through AI algorithms that analyze real-world patient data, leading to more effective treatment outcomes and improved patient adherence in Uganda. This comprehensive review explores the wide-ranging applications of AI in drug discovery, drug delivery dosage form designs, process optimization, testing, and pharmacokinetics/pharmacodynamics (PK/PD) studies in Uganda. This review provides an overview of various AI-based approaches utilized in pharmaceutical technology in Uganda, highlighting their benefits and drawbacks. Nevertheless, the continued investment in and exploration of AI in the pharmaceutical industry offers exciting prospects for enhancing drug development processes and patient care in Uganda.

Keywords: Artificial intelligence; Pharmaceutical Technology; Drug Delivery Design and dosage

1. Introduction

The pharmaceutical industry is essential for addressing global healthcare challenges, including responding to emergencies such as the recent pandemic (Krikorian, & Torreele, 2021). Innovation in this industry relies on extensive research and development in manufacturing technology and customer-oriented marketing strategies (Chavda, et al, 2023). The industry aims to develop new pharmaceutical innovations, from small drug molecules to biologics, with better stability and high potency to meet unmet disease treatment needs. However, addressing the significant levels of toxicity associated with new drugs remains a primary concern, requiring extensive research in the future. Despite advancements, the industry faces challenges and requires further technological developments to meet global medical and healthcare demands (Scannell, et al, 2012). Skilled workforce in the healthcare industry persists, requiring continuous training for healthcare personnel to enhance their involvement in routine duties and address skill gaps through appropriate remedial measures.

* Corresponding author: Onyango Laban Oliver Owin

Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

Approximately 41% of supply chain disruptions occurred in June 2022, marking supply chain disruption as the second most formidable challenge to overcome (Vora, et al 2023). The global outbreak of COVID-19 has caused significant disruptions to various operations worldwide, including ongoing clinical trials (Chavda, et al, 2023). Pandemics, natural catastrophes, pricing changes, cyberattacks, logistical delays, and product issues compound supply chain disruptions. The transportation challenges resulting from the epidemic have devastated the supply chain network and global industries. Decision-induced delays for price updates from suppliers, owing to misunderstandings over whether to use new prices or existing ones for commodities or materials, also create price fluctuation delays.

Due to supply chain disruptions, the pharmaceutical industry has significantly impacted customer satisfaction, corporate reputation, and potential profits (Vora, et al., 2023). The introduction of AI is expected to transform supply chain operations within the pharmaceutical industry and offer practical solutions for various supply chain issues (Vora, et al., 2023). Furthermore, the industry is considering the adoption of AI and virtual platforms to facilitate the supply chain. Resumption or recreation of clinical trials with minimal face-to-face interactions. Cybersecurity threats and data breaches pose significant challenges, as the number of cyberattacks on patient data has increased in the 21st century. Additionally, there needs to be more innovation in trial models, requiring the rework and repetition of ongoing work. Patient recruitment, enrollment, monitoring, retention, and medical adherence in the healthcare sector are vital areas that need special attention due to clinical trials.

2. Current Pharmaceutical Situation and the Role of AI

In the pharmaceutical industry, ongoing research on small molecules improves products and enhances customer satisfaction due to their various advantages. The chemical synthesis process is simple, and the preparation of synthetic derivatives is cost-effective. As a result, numerous stable and potent small-molecule-loaded formulations are available in the pharmacy sector. However, many innovative small molecules face competition from generic molecules, and their launch requires complex data and clinical trials, particularly for treating rare diseases. These processes create economic pressure on companies to focus more on innovation. Nonetheless, the bio-molecular drug industry is increasing to offset the crisis caused by the small size of molecules and limited dissemination of research and innovations.

Small-molecule actions are determined by their conformation and reactivity (Dickherber, et al, 2015). On the other hand, biomolecules, which are larger units, predominantly consist of amino acids from the protein source along with nucleotides or ribonucleotides for nucleic acids. Their stability and function are also influenced by the supramolecular sequence and spatial conformation (Chavda, et al, 2023). Successful products derived from biomolecules include insulin and adalimumab. The pharmacokinetic aspects of these molecules are complex, with infusion being the preferred and most common route of administration. Pharmacokinetic modulation and molecular stabilization are essential aspects of nucleic acid-based research. Achieving pharmacokinetic exposure and enhancing these molecular forms are crucial goals, and new technological advancements may address these challenges and related issues. While AI has significant potential in drug delivery innovation and drug discovery, it still has important limitations that require human intervention to interpret complex results. AI predictions heavily rely on datasets, but interpreting results, particularly in ambiguous situations, necessitates human intervention to reach appropriate conclusions. Algorithmic bias and the assessment of hypotheses pose challenges for AI in processing information for predictions. Moreover, docking simulations may result in the discovery of inactive molecules (Cerón-Carrasco, 2022). Therefore, effective decision-making and cross-verifications require human involvement to eliminate system bias issues. Nonetheless, AI holds potential for possible application, and extensive work may reduce its limitations and make it more effective and reliable.

Regarding AI, the methodology involves utilizing machine learning or its subsets, such as deep learning and natural language processing. The learning process can be supervised or unsupervised, and the type of algorithm used is also critical. Supervised learning involves known inputs (features) and outputs (labels or targets), while unsupervised learning involves unknown outputs. In pharmaceutical product development, various AI models have been explored to enhance different aspects of the process.

3. Analysis

The integration of artificial intelligence in the pharmaceutical industry has been a major focus for many countries globally. Numerous studies have highlighted how different countries have incorporated AI into their pharmaceutical technologies and drug delivery systems (Vora, et al 2023). For example, countries like the United States, China, and the United Kingdom have made significant investments in AI technologies to enhance drug discovery and improve patient care (Chavda, et al, 2023). These nations have utilized AI algorithms to analyze extensive biological data, predict the pharmacokinetics and toxicity of drug candidates, and facilitate personalized medicine approaches (Vora et al., 2023).

Moreover, countries such as Japan and Germany have also been at the forefront of integrating AI in pharmaceutical technologies to optimize research and development processes and improve drug development (Chavda, et al, 2023). Furthermore, India has shown a growing interest in utilizing AI for drug discovery and formulation, with a focus on streamlining drug testing and improving the efficiency of pharmaceutical dosage forms (Vora, et al., 2023).

Collaborative efforts between countries such as Canada and France have focused on establishing international partnerships to further the development and implementation of AI in pharmaceutical technologies, tackle global healthcare challenges, and advance the field of drug delivery design (Chavda, et al., 2023). These collaborative initiatives have facilitated the sharing of knowledge and resources to accelerate the integration of AI in pharmaceutical research and development. Overall, various nations have recognized the potential of AI in revolutionizing the pharmaceutical industry and are actively exploring its applications to improve patient care and address the evolving demands of the healthcare landscape.

4. Way forward

The pharmaceutical industry in Uganda has a promising future, especially with the potential integration of artificial intelligence (AI) in drug discovery, formulation, testing, and drug delivery designs. Adopting AI technology can lead to more efficient and targeted approaches to drug development, potentially increasing the likelihood of successful drug approvals. Furthermore, AI algorithms can optimize research and development processes, potentially reducing development costs and streamlining the testing of pharmaceutical dosage forms in Uganda. Additionally, AI has the potential to facilitate personalized medicine approaches through the analysis of real-world patient data.

The industry does face challenges, such as supply chain disruptions and the need for a skilled workforce. However, adopting AI is expected to transform supply chain operations and offer practical solutions for various supply chain issues. It's also essential to address skill gaps in the industry and provide continuous training for healthcare personnel to enhance their involvement in routine duties. Overall, the pharmaceutical industry in Uganda is poised for growth and innovation. The potential integration of AI and the continuous investment in technological advancements offer exciting prospects for enhancing drug development processes and patient care.

5. Conclusions

AI transforms drug delivery technologies, enabling targeted, personalized, and adaptive therapies. By leveraging AI's data analysis, pattern recognition, and optimization capabilities, pharmaceutical researchers and healthcare professionals can enhance drug efficacy, minimize side effects, and improve patient outcomes. AI-based methods have revolutionized the field of pharmacokinetics and pharmacodynamics. They offer several advantages over traditional experimental methods. AI-based models can predict pharmacokinetic parameters, simulate drug distribution and clearance in the body, and optimize drug dosage and administration routes. AI-based computational methods for PBPK models can simplify the development of such models and optimize their parameters, reducing the need for animal studies and human clinical trials. Computational pharmaceutics, facilitated by AI and big data, revolutionizes drug delivery by providing a more efficient, cost-effective, and data-driven approach. It enables the optimization of drug formulations, personalized therapies, regulatory compliance, and risk reduction, ultimately leading to improved drug manufacturing processes and enhanced patient outcomes. Overall, the integration of AI technologies holds great promise for accelerating drug development, improving patient outcomes, and revolutionizing the pharmaceutical industry, promoting its evolution from Era 4.0 to Era 5.0. the integration of AI technologies in drug delivery has the potential to impact and improve healthcare outcomes in Uganda significantly. With the ability to optimize drug formulations, personalize therapies, and streamline regulatory compliance, AI-driven advancements can result in more effective and efficient healthcare practices, ultimately benefiting patients and healthcare professionals.

Recommendations

- **Collaborate with AI Experts**: Uganda can collaborate with AI experts and research institutions to integrate AI algorithms and machine learning technologies into its pharmaceutical sector. This collaboration can help leverage expertise and resources to develop AI-driven drug discovery, formulation, and testing solutions.
- **Invest in AI Infrastructure:** Uganda should invest in AI infrastructure and technology to support the implementation of AI in pharmaceutical research and development. This includes acquiring AI software, hardware, and data analytics tools to analyze extensive biological data for effective drug discovery and development.

- **Establish a Regulatory Framework**: The government can establish a regulatory framework to govern the use of AI in the pharmaceutical industry. This framework should address ethical considerations, data privacy, and safety standards to ensure responsible and safe implementation of AI technologies.
- **Promote AI Education and Training**: Uganda can promote education and training programs focused on AI applications in pharmaceutical research. This will help to develop a skilled workforce capable of utilizing AI tools and technologies in drug discovery, dosage form design, and clinical trials.
- **Foster Public-Private Partnerships**: Encouraging partnerships between pharmaceutical companies, research institutions, and AI technology providers can accelerate the adoption of AI in Uganda's pharmaceutical industry. Collaboration can lead to joint research projects, technology transfer, and knowledge exchange.
- **Pilot AI Projects:** Uganda can initiate pilot projects to demonstrate the effectiveness of AI in pharmaceutical technology and drug delivery design. These pilot projects can serve as test cases to assess the impact of AI on optimizing drug development processes and improving patient care.

By considering these recommendations, Uganda can prepare for the successful adoption of AI in its pharmaceutical industry, leading to enhanced drug discovery, optimized drug delivery designs, and ultimately improved healthcare outcomes for its population.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Cerón-Carrasco, J. P. (2022). When virtual screening yields inactive drugs: Dealing with false theoretical friends. *ChemMedChem*, *17*(16), e202200278

[2] Chavda, V. P., Vihol, D., Patel, A., Redwan, E. M., & Uversky, V. N. (2023). Introduction to Bioinformatics, AI, and ML for Pharmaceuticals. *Bioinformatics Tools for Pharmaceutical Drug Product Development*, 1-18.

[3] Chavda, V., Bezbaruah, R., Valu, D., Desai, S., Chauhan, N., Marwadi, S., ... & Ding, Z. (2023). Clinical Applications of "Omics" Technology as a Bioinformatic Tool. *Bioinformatics Tools for Pharmaceutical Drug Product Development*, 117-145.

[4] Colombo, S., Beck-Broichsitter, M., Bøtker, J. P., Malmsten, M., Rantanen, J., & Bohr, A. (2018). Transforming nanomedicine manufacturing toward Quality by Design and microfluidics. *Advanced drug delivery reviews*, *128*, 115-131.

[5] Dickherber, A., Morris, S. A., & Grodzinski, P. (2015). NCI investment in nanotechnology: achievements and challenges for the future. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, *7*(3), 251-265.

[6] Krikorian, G., & Torreele, E. (2021). We cannot win the access to medicines struggle using the same thinking that causes the chronic access crisis. *Health and Human Rights*, *23*(1), 119.

[7] Ma, X., Kittikunakorn, N., Sorman, B., Xi, H., Chen, A., Marsh, M., ... & Skomski, D. (2020). Application of deep learning convolutional neural networks for internal tablet defect detection: high accuracy, throughput, and adaptability. *Journal of Pharmaceutical Sciences*, *109*(4), 1547-1557.

[8] Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. *Nature reviews Drug discovery*, *11*(3), 191-200.

[9] Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R., Solanki, H. K., & Chavda, V. P. (2023). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics 2023, 15, 1916.

[10] Yost, E., Chalus, P., Zhang, S., Peter, S., & Narang, A. S. (2019). Quantitative X-ray microcomputed tomography assessment of internal tablet defects. *Journal of Pharmaceutical Sciences*, *108*(5), 1818-1830.